title: [Case of gastric cancer with recurrence of carcinomatous lymphangiosis of the lung 7.6 years after surgery and successfully treated with S-1/low-dose CDDP/Lentinan combination therapy].
abstract: A 78-year-old woman underwent gastrectomy for type 3 gastric cancer with pyloric stenosis, which was detected in November 1997. Thoracic and abdominal CT and other diagnostic procedures were conducted regularly for 5 years after surgery. The patient was recurrence-free and her clinical course was satisfactory. Starting in early May 2005, however, she began to experience respiratory difficulty at exertion, which exacerbated rapidly thereafter. Examination at a department of respiratory physiology led to a diagnosis of a recurrence of stomach cancer and carcinomatous lymphangiosis+lymphatic metastasis to the peritoneal cavity. She was referred to us for palliative care. The accentuated respiratory difficulty was eased with oxygen inhalation and opioid administration. With improvement in her respiratory condition, a combination of S-1 80 mg/day, CDDP 10 mg x once/week and Lentinan 1 mg x twice/week, was initiated. Within about 2 weeks, her respiratory difficulty was eliminated and after 4 weeks x 2 courses, the tumor images were no longer recognized in the thoracic and abdominal CTs. The combination therapy of S-1/low-dose CDDP/Lentinan is free of evident adverse effects and may be a potent therapeutic alternative as a palliative therapy for malignant stomach cancers in elderly patients or those in a poor systemic condition.
authors.affiliation: Dept. of Surgery, Hofu Institute of Gastroenterology.
authors.forename: Keisuke
authors.initials: K
authors.lastname: Matsusaki
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Hirose
authors.forename: Takuji
authors.initials: T
authors.lastname: Yamada
authors.forename: Makoto
authors.initials: M
authors.lastname: Morita
authors.forename: Fumiki
authors.initials: F
authors.lastname: Okamoto
authors.forename: Toyokazu
authors.initials: T
authors.lastname: Kawano
authors.forename: Osamu
authors.initials: O
authors.lastname: Miura
authors.forename: Yukinori
authors.initials: Y
authors.lastname: Okazaki
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Toda
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Minamisono
authors.forename: Susumu
authors.initials: S
authors.lastname: Nagasaki
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007912:Lentinan / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000556:secondary*; D008207:Lymphatic Metastasis / Q000000981:diagnostic imaging / Q000473:pathology; D010094:Oxonic Acid / Q000627:therapeutic use*; D012008:Recurrence; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005641:Tegafur / Q000627:therapeutic use*; D013997:Time Factors; D014057:Tomography, X-Ray Computed
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D007912:Lentinan; D010094:Oxonic Acid; D002945:Cisplatin